Docetaxel, oxaliplatin, 5FU, and trastuzumab as first-line therapy in patients with human epidermal receptor 2-positive advanced gastric or gastroesophageal junction cancer: Preliminary results of a phase II study

The aim of this study is to report first preliminary results of patients enrolled in a phase II study that will investigate the activity and safety of docetaxel, oxaliplatin, and 5-fluorouracil (DOF) in combination with trastuzumab in human epidermal receptor-2 (HER-2) positive patients with advance...

Descripción completa

Detalles Bibliográficos
Autores principales: Roviello, Giandomenico, Petrioli, Roberto, Nardone, Valerio, Rosellini, Pietro, Multari, Andrea Giovanni, Conca, Raffaele, Aieta, Michele
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5976337/
https://www.ncbi.nlm.nih.gov/pubmed/29768350
http://dx.doi.org/10.1097/MD.0000000000010745

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5976337/
https://www.ncbi.nlm.nih.gov/pubmed/29768350
http://dx.doi.org/10.1097/MD.0000000000010745

Ejemplares similares